Insmed Inc
INSM
查看详细走势图
157.750USD
-0.070-0.04%
收盘 01/29, 16:00（美东）报价延迟15分钟
33.53B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.04%
5天
-1.65%
1月
-10.54%
6月
+50.24%
今年开始到现在
-9.36%
1年
+102.24%
查看详细走势图
TradingKey Insmed Inc股票评分
单位: USD 更新时间: 2026-01-29操作建议
Insmed Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名28/393位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价213.78。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Insmed Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Insmed Inc亮点
亮点风险
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
业绩高增长
公司营业收入稳步增长，连续3年增长48.24%
利润高增长
公司净利润处于行业前列，最新年度总收入363.71M美元
估值低估
公司最新PE估值-25.49，处于3年历史低位
机构减仓
最新机构持股214.08M股，环比减少2.39%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值886.00
活跃度降低
近期活跃度降低，过去20天平均换手率0.20
分析师目标
根据
20
位分析师
买入
评级
213.778
目标均价
+31.44%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Insmed Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Insmed Inc简介
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
公司代码INSM
公司Insmed Inc
CEOLewis (William H)
网址https://insmed.com/
相关品种
